<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653822</url>
  </required_header>
  <id_info>
    <org_study_id>0485-CL-J101</org_study_id>
    <nct_id>NCT00653822</nct_id>
  </id_info>
  <brief_title>A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single Dose Study to Assess the Tolerability, Safety, and Pharmacokinetics of Alefacept in Caucasian and Japanese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the pharmacokinetic and pharmacodynamic properties
      and safety profile of alefacept in Caucasian and Japanese healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum alefacept pharmacokinetic parameters</measure>
    <time_frame>Days 1-8,15, 22, 29 and 43</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic parameters of total lymphocyte count and peripheral lymphocyte subsets</measure>
    <time_frame>Days 1-8, 15, 22, 29 and 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety variables including anti-alefacept antibodies</measure>
    <time_frame>Days 1-8, 15, 22, 29 and 43</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Pharmacokinetics of Alefacept</condition>
  <arm_group>
    <arm_group_label>1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1b</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lower SC dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2b</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SC to match lower dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Higher SC dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3b</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SC to match higher dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alefacept</intervention_name>
    <description>IC and SC</description>
    <arm_group_label>1a</arm_group_label>
    <arm_group_label>2a</arm_group_label>
    <arm_group_label>3a</arm_group_label>
    <other_name>Amevive</other_name>
    <other_name>ASP0485</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>IV and SC</description>
    <arm_group_label>1b</arm_group_label>
    <arm_group_label>2b</arm_group_label>
    <arm_group_label>3b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian or Japanese healthy subject with a body mass index (BMI) of 18 to 29 kg/m2,
             inclusive

          -  Japanese subject is first generation, born in Japan from parents of Japanese decent,
             and has resided outside of Japan for 5 years or less OR Caucasian subject is Hispanic
             or non-Hispanic, born of parents of European decent (not Mestizo or mixed race)

          -  Subject must have clinical laboratory test results within the normal therapeutic range
             or, if abnormal, the results are not clinically significant as determined by the
             investigator

        Exclusion Criteria:

          -  CD4+ lymphocyte count outside normal limits at Screening

          -  Received vaccine within 60 days prior to study drug administration

          -  History of drug or alcohol abuse within the 2 years prior to the study drug
             administration

          -  Treatment with any systemic immunosuppressant agent within 6 months prior to study
             drug administration

          -  Treatment with any antibody or biologic product within 6 months prior to study drug
             administration

          -  Treatment with any systemic steroid or steroid inhaler within 2 months prior to study
             drug administration

          -  A smoking habit of greater than 10 cigarettes a day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma US, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=405</url>
    <description>Link to results on JAPIC</description>
  </link>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>February 26, 2013</last_update_submitted>
  <last_update_submitted_qc>February 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amevive</keyword>
  <keyword>alefacept</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Japanese</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alefacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

